Europe Virtual Clinical Trials Market By Study Type (Interventional, Observational, and Expanded Access and Others), By Indication (Oncology, Cardiovascular, Immunology, Gastrointestinal, Respiratory, Endocrinology, Ophthalmology and Other Indications), By Country, Industry Analysis and Forecast, 2020 - 2026
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the Europe Virtual Clinical Trials Market
The Europe Virtual Clinical Trials Market would witness market growth of 7.3% CAGR during the forecast period (2020-2026). Another name for virtual trials is decentralized trials. Virtual trials have a major role to play in the current COVID-19 pandemic and are likely to be a rule in the ways trials and real-world research are run. A virtual technique permits people to participate in the trial from the comfort of their homes which ensures that studies can be continued even when site visits are not feasible. Furthermore, it is a unique method of gathering secure and effective data from participants of clinical researches.
Recently, a rise in the complexity and volume of clinical trials has been observed, which have a significant role to play in the R&D of new drugs and other items. Besides, the cost of clinical trials has been increasing, contributing to the overall cost of creating a drug. Therefore, large pharmaceuticals and small biotechnology companies are searching for innovative methods to enhance trial results and reduce the costs of the trial.
Monitoring of remote patients and virtual visits to physical site visits provide members a choice and comfort of not prone to unnecessary dangers. The virtual examination empowers sponsors to include a bigger population in the research, hence enhancing recruitment, engagement, and retention. Besides, it allows continuous and real-time collection of data with the help of digital health technologies. Finally, virtual connectivity, management, and monitoring can majorly reduce the effort, participants’ burden and time commitments, CRCs, and investigators.
Based on Study Type, the market is segmented into Interventional, Observational, and Expanded Access and Others. Based on Indication, the market is segmented into Oncology, Cardiovascular, Immunology, Gastrointestinal, Respiratory, Endocrinology, Ophthalmology and Other Indications. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include IQVIA Holdings, Inc., ICON PLC, Laboratory Corporation of America Holdings (Covance, Inc.), Dassault Systemes SE (Medidata Solutions, Inc.), Oracle Corporation, Parexel International Corporation (Pamplona Capital Management), PRA Health Sciences, Inc. (KKR & Co., Inc.), Medpace Holdings, Inc., Medable, Inc. and Clinical Ink, Inc. (G.I. Partners)
Scope of the Study
Market Segments Covered in the Report:
By Study Type
- Expanded Access
- Other Indications
- Rest of Europe
- IQVIA Holdings, Inc.
- ICON PLC
- Laboratory Corporation of America Holdings (Covance, Inc.)
- Dassault Systemes SE (Medidata Solutions, Inc.)
- Oracle Corporation
- Parexel International Corporation (Pamplona Capital Management)
- PRA Health Sciences, Inc. (KKR & Co., Inc.)
- Medpace Holdings, Inc.
- Medable, Inc.
- Clinical Ink, Inc. (G.I. Partners)
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free